Searchable abstracts of presentations at key conferences in endocrinology

ea0013p179 | Diabetes, metabolism and cardiovascular | SFEBES2007

A characterisation of novel lipase expression and glucocorticoid regulation of lipolysis in human adipose tissue

Gathercole Laura , Bujalska Iwona , Morgan Stuart , Stewart Paul , Tomlinson Jeremy

Glucocorticoids (GC) have potent actions upon human adipose tissue, promoting adipocyte differentiation, inhibiting preadipocyte proliferation and inducing lipolysis to generate free fatty acids (FFA) and glycerol through a putative action upon hormone sensitive lipase (HSL). FFA have been strongly implicated in the pathogenesis of insulin resistance, yet the molecular mechanisms that cause GC induced lipolysis are not clear. Recently, several novel lipases have been identifie...

ea0013p181 | Diabetes, metabolism and cardiovascular | SFEBES2007

TRB3: A mechanism for glucocorticoid induced insulin sensitisation in human adipocytes

Gathercole Laura , Bujalska Iwona , Stewart Paul , Tomlinson Jeremy

Glucocorticoid (GC) excess is characterized by central obesity, insulin resistance and in some cases, type 2 diabetes mellitus. Whilst it is accepted that GCs cause insulin resistance, both insulin and GCs act synergistically to promote adipocyte differentiation. We have previously shown that GCs cause tissue specific changes in insulin sensitivity, enhancing insulin signalling in human adipose tissue in contrast to muscle.TRB3, a mammalian homolog of <i...

ea0081rc13.6 | Rapid Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Mild autonomous cortisol secretion in patients with adrenal incidentalomas and raised cardiovascular risk

Sagar Rebecca , Fraser Sheila , Collins Emma , Frood Russell , Scarsbrook Andrew , M Stewart Paul , Abbas Afroze

Background: Adrenal incidentalomas are common and require investigation to exclude malignancy and evidence of hormone overproduction. Clinical guidelines recommend overnight dexamethasone suppression tests (ONDST) to assess for cortisol hypersecretion with cortisol levels of 50-138 nmol/l termed “mild autonomous cortisol secretion” (MACS). MACS may be associated with both cardiovascular and metabolic morbidity. We assessed cardiovascular risk in patients with MACS us...

ea0044p35 | Adrenal and Steroids | SFEBES2016

11β-hydroxysteroid dehydrogenase type 1 mediates anti-inflammatory, pro-inflammatory and inflammation-independent effects in primary human dermal fibroblasts

Farraj Layal Abi , Morgan Michael , Alase Adewonuola , Carr Ian , Stewart Paul , Tiganescu Ana

Glucocorticoids (GC) drive multiple adverse effects in skin e.g. epidermal thinning, dermal atrophy and impaired wound healing (WH). Our previous findings indicate increased expression of the GC-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in primary human dermal fibroblasts (HDF), full-thickness skin from older donors and during the inflammatory phase of mouse skin WH. We also reported protection from age-induced dermal atrophy and improved W...

ea0041oc2.5 | Receptors &amp; Signalling | ECE2016

11β-HSD1 is a regulator of brown adipose tissue function and mediates stress adaptation in glucocorticoid excess

Doig Craig , Morgan Stuart , Philp Andrew , Tomlinson Jeremy , Stewart Paul , Lavery Gareth

Glucocorticoids (GC) are critical to stress adaptation but in excess (Cushing’s syndrome) drive metabolic dysfunction. 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1) amplifies intracellular GC signaling with 11β-HSD1KO mice protected from the side-effects of GC excess. Brown adipose tissue (BAT) function is impaired by GC’s, which repress UCP1 and beta-adrenergic stimulated thermogenesis. Identifying mechanisms regulating BAT function is important a...

ea0041gp16 | Adrenal (1) | ECE2016

Increased morbidity and hospital admissions in patients with adrenal insufficiency

Stewart Paul M , Biller Beverly MK , Marelli Claudio , Gunnarsson Candace , Ryan Michael , Johannsson Gudmundur

Introduction: Patients with adrenal insufficiency (AI) (primary (PAI), secondary to pituitary disease (PIT) and congenital adrenal hyperplasia (CAH)) have reduced life expectancy with reported standardized mortality ratios of ~2:1 but given the rarity of AI, the underlying explanation remains largely unknown.Objective: To evaluate patient characteristics, prevalence of concomitant conditions and hospitalization incidence in patients with AI compared to a...

ea0037gp.01.02 | Adrenal | ECE2015

Defining and exploring the excessive healthcare burden of adrenal insufficiency

Stewart Paul , Biller Beverly M K , Marelli Claudio , Gunnarsson Candace , Ryan Michael , Johannsson Gudmundur

Introduction: The clinical outcome of patients with adrenal insufficiency (AI) has been shown to be less favorable than previously thought. Clinical studies have shown increased mortality, reduced cardiovascular and skeletal health and compromised quality of life, but the impact of this upon healthcare burden is unknown. This research utilised real-world evidence to compare comorbidities, healthcare utilization and expenditures in patients with AI.Method...

ea0034oc3.4 | Steroids | SFEBES2014

Pre-receptor glucocorticoid metabolism across human ageing: the impact of gender and menopausal status

Hassan-Smith Zaki , Morgan Stuart , Sherlock Mark , Hughes Beverly , Lavery Gareth , Tomlinson Jeremy , Stewart Paul

Introduction: There is growing evidence that 11β-HSD1 expression/activity increases with age in key target tissues including adipose tissue, bone, and skin, implicating local amplification of glucocorticoids in the pathophysiology of related disease. We have previously shown that 11β-HSD1KO mice are protected from both the adverse metabolic effects of excess glucocorticoids and age-associated muscle weakness. We investigated changes in global activity and skeletal mu...

ea0034oc6.1 | Clinical | SFEBES2014

Adverse outcome in glucocorticoid induced adrenal suppression; an analysis of short synacthen tests in 2782 patients

Chapman Matthew , Argese Nicola , Mani Dhanasekaran , Dabhi Vijay , Boot Christopher , Crowley Rachel , Stewart Paul , Tomlinson Jeremy

2–3% of the UK population are prescribed glucocorticoid (GC) therapy and their adverse effects contribute to a significant health burden. Suppression of endogenous GC secretion is a recognized complication of therapy, but the magnitude of the problem, together with its clinical consequences have not been determined. We conducted a retrospective study across all specialties in a large secondary–tertiary care center identifying 2782 patients who underwent 3666 250 &#95...